These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30465208)

  • 1. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
    Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
    Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
    Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen J; Jiang CC; Jin L; Zhang XD
    Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
    Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis.
    Romano S; Tufano M; D'Arrigo P; Vigorito V; Russo S; Romano MF
    Semin Cancer Biol; 2020 Feb; 60():181-190. PubMed ID: 31422157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
    Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L
    J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
    Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
    Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 Detection on Circulating Melanoma Cells.
    Po JW; Ma Y; Balakrishnar B; Brungs D; Azimi F; Cooper A; Saricilar E; Murthy V; de Souza P; Becker TM
    Methods Mol Biol; 2021; 2265():223-233. PubMed ID: 33704718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
    Po JW; Ma Y; Balakrishna B; Brungs D; Azimi F; de Souza P; Becker TM
    PLoS One; 2019; 14(2):e0211866. PubMed ID: 30735560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
    Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
    Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.
    Mensali N; Dillard P; Fayzullin A; Köksal H; Gaudernack G; Kvalheim G; Inderberg EM; Wälchli S
    FASEB J; 2021 Sep; 35(9):e21750. PubMed ID: 34424568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.